Laura Quinn

Senior Translational Manager
Greywolf Therapeutics
Oxford, England, United Kingdom

Disclosure information not submitted.

Presentation(s):

• Therapeutic Development for Axial Spondyloarthritis: ERAP-1 Inhibition by GRWD0715 Results in Auto-Antigen Loss on HLA-B*27 and the Inhibition of Cognate CD8⁺ T Cell Responses

  Wednesday, June 25, 2025
  4:15pm - 4:30pm East Coast USA Time